
|Videos|June 9, 2022
Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG
Author(s)Urology Times staff
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
Advertisement
In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
2
Taylor Goodstein, MD, highlights contemporary experience with gene therapies for NMIBC
3
Jim Hu, MD, discusses new posterior approach to nerve-sparing prostatectomy
4
Permanent J code for mitomycin for intravesical solution now in effect
5



















